Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crifortinib Besylate Combined With Chemotherapy in Newly-treated AML
NCT05133882Phase 2Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizotinib in acute myeloid leukemia (AML) (3 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Tolerated Dose and Composite Complete Remission Rate up to 12 months. Started Oct 2022; status: recruiting.
02
Drugs
crizotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05133882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133882.